Pharmacy Journal Examines Compounded GLP-1 Drugs After Shortages Ease

A commentary in the Am J Health Syst Pharm, titled according to its PubMed listing, looks at the policy and safety questions surrounding compounded GLP-1 receptor agonists now that manufacturer supply shortages for drugs like semaglutide and tirzepatide are easing.

During the shortage years, state licensed compounding pharmacies were legally permitted to prepare versions of these medications to fill gaps left by branded manufacturers. As supply has normalized, that legal allowance narrows, since compounding exceptions under federal law generally apply only while a drug remains on an official shortage list. This creates a transition period where health systems, pharmacists, and patients must navigate changing rules about what can still be dispensed and under what conditions.

The piece frames this as a balancing act: maintaining patient access for those who relied on compounded formulations, often for cost reasons, while addressing legitimate concerns about quality control, dosing accuracy, and oversight that differ between FDA approved manufactured products and pharmacy compounded preparations. These are the kinds of operational and regulatory considerations hospital and health system pharmacists are now working through as the compounding landscape shifts.

This piece appears to be a professional discussion rather than a report of new clinical data.

This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.